Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amarendra Pegu

Showing results (11-20 of 89) with videos related to

Pageof 9
Sort By:
Iscience|September 26, 2022
Anti-viral efficacy of a next-generation CD4-binding site bNAb in SHIV-infected animals in the absence of anti-drug antibody responsesSarah E Lovelace, Sabrina Helmold Hait, Eun Sung Yang, et al.
The Journal of Clinical Investigation|April 18, 2018
Accumulation of follicular CD8+ T cells in pathogenic SIV infectionSara Ferrando-Martinez, Eirini Moysi, Amarendra Pegu, et al.
The Journal of Clinical Investigation|October 8, 2021
Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent stagingJoana Dias, Giulia Fabozzi, Kylie March, et al.
Nature|April 28, 2016
A single injection of anti-HIV-1 antibodies protects against repeated SHIV challengesRajeev Gautam, Yoshiaki Nishimura, Amarendra Pegu, et al.
JCI Insight|December 17, 2020
Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria preventionNeville K Kisalu, Lais D Pereira, Keenan Ernste, et al.
Journal of Virology|August 4, 2017
Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus MonkeysBoris Julg, Devin Sok, Stephen D Schmidt, et al.
Plos Pathogens|May 15, 2019
Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaquesGiulia Calenda, Ines Frank, Géraldine Arrode-Brusés, et al.
Antimicrobial Agents and Chemotherapy|August 27, 2025
Fostemsavir analog BMS-818251 has enhanced viral neutralization potency and similar escape mutation profileYen-Ting Lai, Adam S Dingens, Megan DeMouth, et al.
Journal of Virology|November 20, 2015
Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral ReservoirsDiane L Bolton, Amarendra Pegu, Keyun Wang, et al.
Plos Pathogens|May 3, 2018
Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturationEma T Crooks, Samantha L Grimley, Michelle Cully, et al.
Pageof 9

Showing results (11-20 of 89) with videos related to

Sort By:
Pageof 9
Iscience|September 26, 2022
Anti-viral efficacy of a next-generation CD4-binding site bNAb in SHIV-infected animals in the absence of anti-drug antibody responsesSarah E Lovelace, Sabrina Helmold Hait, Eun Sung Yang, et al.
The Journal of Clinical Investigation|April 18, 2018
Accumulation of follicular CD8+ T cells in pathogenic SIV infectionSara Ferrando-Martinez, Eirini Moysi, Amarendra Pegu, et al.
The Journal of Clinical Investigation|October 8, 2021
Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent stagingJoana Dias, Giulia Fabozzi, Kylie March, et al.
Nature|April 28, 2016
A single injection of anti-HIV-1 antibodies protects against repeated SHIV challengesRajeev Gautam, Yoshiaki Nishimura, Amarendra Pegu, et al.
JCI Insight|December 17, 2020
Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria preventionNeville K Kisalu, Lais D Pereira, Keenan Ernste, et al.
Journal of Virology|August 4, 2017
Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus MonkeysBoris Julg, Devin Sok, Stephen D Schmidt, et al.
Plos Pathogens|May 15, 2019
Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaquesGiulia Calenda, Ines Frank, Géraldine Arrode-Brusés, et al.
Antimicrobial Agents and Chemotherapy|August 27, 2025
Fostemsavir analog BMS-818251 has enhanced viral neutralization potency and similar escape mutation profileYen-Ting Lai, Adam S Dingens, Megan DeMouth, et al.
Journal of Virology|November 20, 2015
Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral ReservoirsDiane L Bolton, Amarendra Pegu, Keyun Wang, et al.
Plos Pathogens|May 3, 2018
Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturationEma T Crooks, Samantha L Grimley, Michelle Cully, et al.
Pageof 9